EUVIMEDEUVIMED entdecken
Open Access

Trametinib in Patients With NF1- , GNAQ- , or GNA11 -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

Kari B Wisinski iD, Yael Flamand iD, Melissa A Wilson iD, Jason J Luke iD, Hussein A Tawbi iD, Fangxin Hong iD, Edith P Mitchell, James A Zwiebel iD, Helen Chen, Robert J Gray iD, Shuli Li, Lisa M McShane iD und 12 weitere

JCO Precision Oncology · 2023

DOI: 10.1200/po.22.00421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Kari B Wisinski und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Melanoma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE NCI-MATCH is a precision medicine trial using genomic testing to allocate patients with advanced malignancies to targeted treatment subprotocols. This report combines two subprotocols evaluating trametinib, a MEK1/2 inhibitor, in patients with Neurofibromatosis 1 ( NF1[S1] or GNA11/Q [S2]) altered tumors. METHODS Eligible patients had tumors with deleterious inactivating NF1 or GNA11/Q mutations by the customized Oncomine AmpliSeq panel. Prior MEK inhibitor treatment was excluded. Glioblastomas (GBMs) were permitted, including malignancies associated with germline NF1 mutations (S1 only). Trametinib was administered at 2 mg once daily over 28-day cycles until toxicity or disease progression. Primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS) at 6 months, PFS, and overall survival. Exploratory analyses included co-occurring genomic alterations and PTEN loss. RESULTS Fifty patients were eligible and started therapy: 46 with NF1 mutations (S1) and four with GNA11 mutations (S2). In the NF1 cohort, nonsense single-nucleotide variants were identified in 29 and frameshift deletions in 17 tumors. All in S2 had nonuveal melanoma and GNA11 Q209L variant. Two partial responses (PR) were noted in S1, one patient each with advanced lung cancer and GBM for an ORR of 4.3% (90% CI, 0.8 to 13.1). One patient with melanoma in S2 had a PR (ORR, 25%; 90% CI, 1.3 to 75.1). Prolonged stable disease (SD) was also noted in five patients (four in S1 and one in S2) with additional rare histologies. Adverse events were as previously described with trametinib. Comutations in TP53 and PIK3CA were common. CONCLUSION Although these subprotocols did not meet the primary end point for ORR, significant responses or prolonged SD noted in some disease subtypes warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibromatosis 1MelanomaHumansPyrimidinonesPyridonesGTP-Binding Protein alpha Subunits, Gq-G11GTP-Binding Protein alpha Subunits

Substanzen

trametinibPyrimidinonesPyridonesGNAQ protein, humanGTP-Binding Protein alpha Subunits, Gq-G11GNA11 protein, humanGTP-Binding Protein alpha Subunits

Autor:innen und Institutionen

  • Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI.
  • Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA.
  • Department of Oncology, Division of Hematology/Medical Oncology, St Luke's University Health Network, Easton, PA.
  • Division of Hematology/Oncology, University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA.
  • MD Anderson Cancer Center, Houston, TX.
  • Thomas Jefferson University Hospital, Philadelphia, PA.

ORCID-Profile: Kari B Wisinski, Yael Flamand, Melissa A Wilson, Jason J Luke, Hussein A Tawbi, Fangxin Hong, James A Zwiebel, Robert J Gray, Lisa M McShane, Lawrence V Rubinstein, David Patton, P Mickey Williams, Stanley R Hamilton, Robert J Behrens, Kathryn P Pennington, Barbara A Conley, Lyndsay N Harris, Alice P Chen, Keith T Flaherty

Förderung

  • NCI NIH HHS

Zitieren

APA

Wisinski, K. B., Flamand, Y., Wilson, M. A., Luke, J. J., Tawbi, H. A., Hong, F., Mitchell, E. P., Zwiebel, J. A., Chen, H., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Behrens, R. J., Pennington, K. P., Conley, B. A., …, & Flaherty, K. T. (2023). Trametinib in Patients With NF1- , GNAQ- , or GNA11 -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO Precision Oncology. https://doi.org/10.1200/po.22.00421

Vancouver

Wisinski KB, Flamand Y, Wilson MA, Luke JJ, Tawbi HA, Hong F, et al. Trametinib in Patients With NF1- , GNAQ- , or GNA11 -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO Precision Oncology. 2023. doi:10.1200/po.22.00421

BibTeX
@article{Wisinski2023,
  author = {Wisinski, Kari B and Flamand, Yael and Wilson, Melissa A and Luke, Jason J and Tawbi, Hussein A and Hong, Fangxin and Mitchell, Edith P and Zwiebel, James A and Chen, Helen and Gray, Robert J and Li, Shuli and McShane, Lisa M and Rubinstein, Lawrence V and Patton, David and Williams, P Mickey and Hamilton, Stanley R and Behrens, Robert J and Pennington, Kathryn P and Conley, Barbara A and Arteaga, Carlos L and Harris, Lyndsay N and O'Dwyer, Peter J and Chen, Alice P and Flaherty, Keith T},
  title = {Trametinib in Patients With NF1- , GNAQ- , or GNA11 -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2},
  journal = {JCO Precision Oncology},
  year = {2023},
  doi = {10.1200/po.22.00421}
}
Kostenlos starten →